Search results for "Enfermedad transmisible"

showing 2 items of 2 documents

Underlying heart diseases and acute COVID-19 outcomes

2021

Background: The presence of any underlying heart condition could influence outcomes during the coronavirus disease 2019 (COVID-19). Methods: The registry HOPE-COVID-19 (Health Outcome Predictive Evaluation for COVID-19, NCT04334291) is an international ambispective study, enrolling COVID-19 patients discharged from hospital, dead or alive. Results: HOPE enrolled 2798 patients from 35 centers in 7 countries. Median age was 67 years (IQR: 53.0-78.0), and most were male (59.5%). A relevant heart disease was present in 682 (24%) cases. These were older, more frequently male, with higher overall burden of cardiovascular risk factors (hypertension, dyslipidemia, diabetes mellitus, smoking habit, …

Malemedicine.medical_specialtyHeart DiseasesHeart diseaseInfecciones por coronavirusEnfermedad cardiovascularEnfermedad transmisibleheart diseaseComorbidityregistry030204 cardiovascular system & hematologyGlobal HealthSepsis03 medical and health scienceschemistry.chemical_compound0302 clinical medicineTocilizumabRisk FactorsDiabetes mellitusInternal medicinemedicineHumansRegistriesPandemicsAgedRetrospective StudiesSARS-CoV-2business.industryCOVID-19HydroxychloroquineGeneral MedicineMiddle AgedPrognosismedicine.diseasemortalitychemistrycardiologyHeart failureCohortCardiologyFemaleCardiology and Cardiovascular MedicinebusinessDyslipidemiamedicine.drugCardiology Journal
researchProduct

Renin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: Final analysis of the international HOPE COVID-19 …

2021

Background The use of Renin-Angiotensin system inhibitors (RASi) in patients with coronavirus disease 2019 (COVID-19) has been questioned because both share a target receptor site. Methods HOPE-COVID-19 (NCT04334291) is an international investigator-initiated registry. Patients are eligible when discharged after an in-hospital stay with COVID-19, dead or alive. Here, we analyze the impact of previous and continued in-hospital treatment with RASi in all-cause mortality and the development of in-stay complications. Results We included 6503 patients, over 18 years, from Spain and Italy with data on their RASi status. Of those, 36.8% were receiving any RASi before admission. RASi patients were …

QA75Malemedicine.medical_specialtyHeart diseaseInfecciones por coronavirusmedicine.medical_treatmentInhibidores enzimáticosPopulationClinical InvestigationsEnfermedad transmisibleAngiotensin-Converting Enzyme InhibitorsSistema renina-angiotensinaComorbidity030204 cardiovascular system & hematologySeverity of Illness Index03 medical and health sciences0302 clinical medicineRisk FactorsOutcome Assessment Health CareSeverity of illnessmedicineHumansRegistries030212 general & internal medicineMedical prescriptioneducationHeart FailureMechanical ventilationeducation.field_of_studySARS-CoV-2business.industryCOVID-19Middle AgedPrognosismedicine.diseaseR1Respiration ArtificialComorbidityHospitalizationItalySpainHeart failureEmergency medicineFemaleObservational studyCardiology and Cardiovascular MedicinebusinessAmerican Heart Journal
researchProduct